Interestingly, the KOR agonist TRK820 (nalfurafine), which has been clinically approved in Japan for use in hemodialysis-related uremic pruritus, could be useful for tumor therapy by suppressing tumor angiogenesis, and thus could offer therapeutic benefits beyond the relief of cancer pain. The gene discussed is OPRK1; the disease is cancer.